Perrigo (NYSE:PRGO) Issues FY 2025 Earnings Guidance

Perrigo (NYSE:PRGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.700-2.80 for the period, compared to the consensus EPS estimate of 2.960. The company issued revenue guidance of -, compared to the consensus revenue estimate of $4.4 billion.

Perrigo Stock Performance

PRGO stock traded down $4.68 during trading hours on Wednesday, reaching $15.51. The stock had a trading volume of 6,318,348 shares, compared to its average volume of 1,595,668. The stock has a market capitalization of $2.13 billion, a PE ratio of -26.87 and a beta of 0.43. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.32 and a quick ratio of 1.24. The stock has a 50-day simple moving average of $21.88 and a 200 day simple moving average of $24.62. Perrigo has a fifty-two week low of $15.58 and a fifty-two week high of $30.93.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 earnings per share. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Analysts predict that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 16th. Investors of record on Friday, November 28th will be given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 7.5%. The ex-dividend date of this dividend is Friday, November 28th. Perrigo’s dividend payout ratio (DPR) is currently -200.00%.

Analyst Ratings Changes

A number of research firms recently commented on PRGO. Canaccord Genuity Group lowered their price target on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. JPMorgan Chase & Co. lowered their price target on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings reissued a “sell (d)” rating on shares of Perrigo in a report on Wednesday, October 8th. Finally, Jefferies Financial Group decreased their target price on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $31.25.

Insider Activity

In related news, Director Geoffrey M. Parker bought 4,375 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were bought at an average price of $22.97 per share, for a total transaction of $100,493.75. Following the transaction, the director directly owned 33,287 shares of the company’s stock, valued at approximately $764,602.39. The trade was a 15.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Abigail Lennox bought 1,255 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average price of $22.41 per share, for a total transaction of $28,124.55. Following the transaction, the executive vice president directly owned 1,255 shares in the company, valued at $28,124.55. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 10,118 shares of company stock worth $232,699 over the last quarter. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PRGO. Ion Asset Management Ltd. lifted its position in shares of Perrigo by 34.7% during the 2nd quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after acquiring an additional 983,727 shares during the period. Goldman Sachs Group Inc. raised its holdings in Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares during the last quarter. State Street Corp raised its holdings in Perrigo by 9.5% during the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after buying an additional 637,678 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Perrigo by 52.5% during the second quarter. Ameriprise Financial Inc. now owns 1,308,334 shares of the company’s stock worth $34,959,000 after buying an additional 450,247 shares during the last quarter. Finally, Quantinno Capital Management LP raised its holdings in Perrigo by 149.9% during the second quarter. Quantinno Capital Management LP now owns 527,588 shares of the company’s stock worth $14,097,000 after buying an additional 316,466 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.